II. Differential Diagnosis
III. Mechanisms
- Drug-absorption or Hapten-induced
- Medication coats Red Blood Cell surface
- Induces IgG Antibody production
- Immune-complex
- Drug stimulates IgM production and binding
- Drug-IgM complex binds RBC and complement induced
- Autoantibody
- Drug stimulates IgG production against RBC membrane
IV. Causes: By Mechanism
-
Immune Hemolytic Anemia
- Beta-Lactamase Inhibitors (e.g. Sulbactam, Clavulanic Acid, Tazobactam)
- Cefotetan (common)
- Ceftriaxone (common)
- Fludarabine
- Intravenous Immunoglobulin (IV Ig)
- Methyldopa (common in past)
- NSAIDs (common)
- Penicillin (common in past)
- Piperacillin with Tazobactam or Zosyn (common)
- Thrombotic Microangiopathic Anemia (only 5% of MAHA Cases)
- Adalimumab (Humira)
- Bupropion (Wellbutrin)
- Chemotherapy
- Clopidogrel (Plavix)
- Cocaine
- Covid Vaccine (AstraZeneca and Johnson and Johnson Vaccine induced immune TTP, 5 to 30 days after dose)
- Cyclosporine (common cause)
- Gemcitabine (Gemzar)
- Ibuprofen
- Interferon
- Mefloquine
- Methylenedioxymethamphetamine (MDMA, Ecstacy)
- Metronidazole (Flagyl)
- Nitrofurantoin (Macrobid)
- Oxaliplatin (Eloxatin)
- Quetiapine (Seroquel)
- Quinine (common cause)
- Simvastatin (Zocor)
- Tacrolimus (Prograf, common cause)
- Trimethoprim Sulfamethoxazole (Bactrim, Septra)
- Oxidation Hemolysis
V. Causes: Extravascular (IgG) vs Intravascular Hemolysis (C3)
VI. References
- Ford (2001) Clinical Toxicology, p. 201-3
- Dhaliwal (2004) Am Fam Physician 69:2599-606 [PubMed]
- Lubran (1989) Ann Clin Lab Sci 19:114-21 [PubMed]